FDA endorses new regimen for deadly drug-resistant tuberculosis rampant in developing world
The bacteria behind tuberculosis do not discriminate — they are all-pervasive, but the highest burden of disease is borne by poorer nations. Like many other forms of bacteria, TB-causing bacteria have rapidly mutated to become drug-resistant — and for those inflicted with these strains, options are limited and prognosis feeble. In a first, the FDA on Wednesday approved a three-drug cocktail developed by a nonprofit organization that is engineered to help those with the stubborn form of TB that has failed to respond to conventional therapy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 73,300+ biopharma pros reading Endpoints daily — and it's free.